Peptide education

SS-31 / Elamipretide

Elamipretide · MTP-131 · Bendavia · Forzinity · elamipretide hydrochloride

SS-31 is elamipretide, a four-amino-acid peptide built to stick to cardiolipin, the lipid that holds the inner mitochondrial membrane together. It is rare in this market: a peptide-world name with a real FDA approval behind it. Forzinity, a daily subcutaneous injection, is approved to improve muscle strength in Barth syndrome patients who weigh at least 30 kg. Everything else it is known for, mitochondrial myopathy, eye disease, heart failure, energy, longevity, is a trial that missed, a trial still running, or a clinic claim. And the approved drug is not the same product as the vial sold online under the same name.

SS-31 earned a real approval for one narrow thing: muscle strength in Barth syndrome, and even that rests on an open-label strength endpoint that still needs a confirmatory trial. The longer list of other uses is a mix of failed phase 3s, early signals, and forum reports.

By the Peptides Media Editorial Team Editorial policy14 min read

Primary useBarth syndrome muscle strength

EvidenceApproved for Barth; mixed elsewhere

Common routeSubcutaneous; topical in LHON study

Off-label supportReports and clinic pages

Product issueApproved drug differs from vendor vials

Overview

Quick answer

Forzinity is a specific 80 mg/mL sterile subcutaneous drug product. A research vial, clinic protocol, Reddit report, or seller listing that uses the SS-31 or elamipretide name may involve a different material, with different testing, sterility, concentration, storage, and handling.

What is it?

SS-31 is elamipretide, also called MTP-131 or Bendavia, a synthetic tetrapeptide designed to bind cardiolipin on the inner mitochondrial membrane. The idea is to stabilize that membrane so the mitochondrion makes energy with less waste and less oxidative leak.

What is it approved for?

One thing: Forzinity is approved, under accelerated approval, to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg. The approval leans on open-label knee extensor strength gains, and FDA still requires a confirmatory randomized trial.

What do people use or discuss it for outside that?

The trial record covers primary mitochondrial myopathy, dry AMD, LHON, heart failure, and kidney protection during renal artery procedures. The internet adds fatigue, ME/CFS, long COVID, brain fog, aging, and stacks with MOTS-c or NAD+, which is clinic and Reddit territory, not trial territory.

What route, amount, and schedule details appear in the sources?

The label says 40 mg under the skin once daily, 20 mg daily for adults with severe renal impairment who are not on dialysis. Trials mostly used the same 40 mg daily for 12 to 48 weeks; the LHON study used a topical eye solution. Protocol websites selling 5 to 10 mg cycles describe market practice, not any studied regimen.

Why do SS-31 claims differ by setting?

Because the settings share a molecule and not much else. The Barth label, a missed phase 3 in mitochondrial myopathy, a topical eye study, a clinic energy pitch, and a gray-market vial each rest on different products, doses, endpoints, and quality controls.

Reported practice

Commonly reported protocol

SS-31 / Elamipretide community-reported use

Route

Trial work used intravenous and subcutaneous administration; community material describes subcutaneous cycles

Typical amount

No consistent community range; one protocol-style site describes 5 to 10 mg daily market schedules

Frequency

Not established

Duration

Not established

No established community protocol. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail

Evidence

Evidence snapshot

Best-supported useBarth syndrome muscle strength

FDA granted accelerated approval for Forzinity to improve muscle strength in Barth syndrome patients weighing at least 30 kg, but the approval still requires a confirmatory randomized trial.

FDA

Randomized Barth endpointsStrength data, weaker walking and fatigue data

The randomized Barth study did not show superiority on 6-minute walk distance or fatigue. Open-label knee extensor strength gains became the accelerated-approval basis, which is why the confirmatory trial matters.

FDA

Primary mitochondrial myopathyEarly studies, phase 3 miss

Early PMM work suggested possible exercise-related benefit, but MMPOWER-3 found no overall improvement in 6-minute walk distance or fatigue at 24 weeks. Genotype-subgroup claims remain exploratory unless prospectively confirmed and peer reviewed.

PMID 29500292 PMID 32096613 PMID 37268435 PMID 39574155 NCT05162768

Vision researchInvestigational AMD and LHON findings

Dry AMD and LHON studies keep elamipretide in the ophthalmology conversation, with exploratory visual-function and retinal-structure findings. They are reasons to keep studying elamipretide, not to treat a peptide-market vial as a vision product.

PMID 36246181 PMID 36246187 PMID 39605874 NCT06373731 PMID 37923251

Heart and kidney programsMixed and narrow

Heart failure work had mechanistic interest but PROGRESS-HF did not beat placebo on left ventricular end-systolic volume at 4 weeks. A renal revascularization pilot reported favorable procedural kidney signals, but it was small and highly specific.

PMID 29217757 PMID 32068002 PMID 28916603

Common off-label discussionEnergy, recovery, aging, cognition, ME/CFS, long COVID

Clinic pages, gray-market listings, and Reddit threads discuss SS-31 as a mitochondrial support peptide for energy, fatigue, recovery, aging, brain fog, mental energy, ME/CFS, and long COVID. Those sources explain the goals people attach to SS-31, while controlled outcome data for those exact goals are still mostly anecdotal or clinic-driven.

Clinic Reddit Vendor

Product-quality riskA COA is a starting point

Vendor COAs and HPLC purity claims may help with identity or purity, but they do not show sterile injectable quality, representative lot sampling, shipping validation, FDA-reviewed release controls, or approved labeling.

FDA FTC Vendor

Claims

Common claims vs evidence

Claim	Human evidence	Mechanistic evidence	Anecdotal evidence	Verdict
SS-31 is FDA-approved.	Forzinity, the approved elamipretide product, is approved under accelerated approval to improve muscle strength in Barth syndrome patients weighing at least 30 kg. That is the approval people are referring to when they say SS-31 is approved.	Barth syndrome is biologically tied to cardiolipin abnormalities, which makes the cardiolipin-centered mechanism unusually relevant to this disease compared with broad wellness claims.	Online discussions sometimes shorten this to "SS-31 is FDA-approved," which can make gray-market SS-31 vials sound like the approved product.	Plainly: Forzinity is approved for Barth syndrome muscle strength. A research vial, compounded product, clinic protocol, or off-label use has to be judged on its own evidence. FDA
SS-31 improves fatigue and walking capacity in Barth syndrome.	The randomized Barth study did not show superiority over placebo on 6-minute walk distance or fatigue. The approval instead leaned on knee extensor muscle-strength gains seen in open-label follow-up.	A mitochondrial cardiolipin mechanism supports muscle-function research in Barth syndrome, but that rationale did not convert every functional endpoint into a randomized win.	Families, advocates, and online discussions may focus on functional improvement themes, but the measured endpoints matter: 6-minute walk distance and fatigue did not separate cleanly in the randomized period; knee extensor strength improved in open-label follow-up.	The approved-product claim is muscle strength. Fatigue and walking-capacity claims are weaker because the randomized period did not show the same clear separation, and the confirmatory trial is still part of the approval requirement. FDA
SS-31 works for primary mitochondrial myopathy.	Early PMM studies reported encouraging exercise-performance results, but the larger MMPOWER-3 phase 3 trial did not improve the 6-minute walk test or fatigue overall after 24 weeks.	PMM is a logical test case for a mitochondrial membrane-targeted drug. The negative phase 3 result shows that a coherent mitochondrial rationale can still miss the walking-distance and fatigue endpoints patients would actually care about.	Clinic and forum discussion often turns "mitochondrial support" into fatigue and energy language, but the phase 3 result clearly limits broad PMM claims.	After MMPOWER-3, PMM reads as a research area rather than a broad treatment claim. Genotype-specific and NuPOWER findings remain narrower hypotheses built from registry, post hoc, or company-reported sources. PMID 29500292 PMID 32096613 PMID 37268435 PMID 39574155 NCT05162768
SS-31 may help selected mitochondrial genotypes.	Post hoc genotype analyses and the NuPOWER program support a more focused research question in selected nuclear-DNA-related mitochondrial disease, but they narrow the question to selected genotypes rather than all mitochondrial disease.	If downstream mitochondrial membrane dysfunction is prominent in a subgroup, elamipretide remains a mechanistic research candidate. The clinical question is whether that biology predicts a reproducible endpoint.	People in mitochondrial-disease and fatigue communities sometimes use subgroup language as a reason to try it outside specialist care. The human data are still exploratory until prospective studies repeat the result.	A real research lead, but not a reason to assume SS-31 treats every mitochondrial condition. PMID 39574155 NCT05162768 Reddit
SS-31 is an investigational therapy for dry AMD or LHON.	Dry AMD phase 1 and phase 2 studies reported exploratory visual-function, low-luminance, ellipsoid-zone, or geographic-atrophy-related signals, and ReNEW is registered as a phase 3 dry AMD program. A small topical LHON study reported safety, tolerability, and potential efficacy.	Retina and optic-nerve disorders have high mitochondrial energy demands, so mitochondrial membrane stabilization is a reasonable research strategy.	Online vision-restoration language can run far ahead of the studies. The human research keeps elamipretide in ophthalmology research, but it is not a consumer vision-restoration claim.	The AMD and LHON data keep elamipretide in ophthalmology research: early visual-function, retinal-structure, and topical-safety signals, but no approved vision-restoration use. PMID 36246181 PMID 36246187 PMID 39605874 NCT03891875 NCT06373731 PMID 37923251 NCT02693119
SS-31 helps heart failure or cardioprotection.	A single-infusion heart-failure study showed favorable mechanistic or left-ventricular-volume signals, but PROGRESS-HF, a multiple-dose phase 2 trial, did not improve left ventricular end-systolic volume versus placebo after 4 weeks.	The heart is mitochondria-dense, and cardiolipin biology plausibly connects to energetic stress. The human heart-failure result still has to come from trials, and PROGRESS-HF missed its structural endpoint.	Clinic and longevity pages sometimes fold cardioprotection into broad mitochondrial marketing. That is extrapolation unless it names the actual heart-failure data and its limits.	The heart-failure data are mixed, and the larger multiple-dose structural endpoint missed. That leaves a narrow research summary, not an established heart-failure treatment claim. PMID 29217757 PMID 32068002 NCT02788747 Clinic
SS-31 may protect kidneys during renal revascularization.	A small phase 2a pilot in atherosclerotic renal artery stenosis during percutaneous transluminal renal angioplasty reported attenuation of postprocedural hypoxia, increased renal blood flow, and improved kidney function.	Ischemia-reperfusion injury is a mitochondrial-stress setting, which is why the pilot was run.	Kidney discussion around SS-31 is less common than energy or longevity talk. The concrete signal is the small procedural renal-revascularization pilot.	This belongs as a pilot-study finding. It is not a broad kidney-health or renal-repair claim. PMID 28916603
SS-31 is an anti-aging, longevity, recovery, or energy peptide.	There is no established human anti-aging or healthy-person energy outcome in the published human studies. The human programs are disease-specific and mixed outside Barth syndrome.	The cardiolipin and mitochondrial bioenergetics mechanism is credible, and preclinical aging or exercise-tolerance work helps explain why the longevity community cares. Mechanism and animal data are not human lifespan, vitality, or recovery data.	Clinic pages, vendor claims, online peptide-protocol sites, and forums describe SS-31 for energy, recovery, oxidative stress, aging, brain fog, and mental energy. Reddit and forum discussions often place it beside MOTS-c, NAD boosters, NR, BPC-157, hyperbaric oxygen, breathwork, Selank, CBD, or broader chronic-fatigue stacks.	People discuss or report using SS-31 for energy, recovery, and longevity goals. The support is mechanism, clinic pages, and reports rather than human anti-aging outcomes. PMID 24117165 PMC Clinic Reddit
SS-31 helps ME/CFS or long COVID fatigue.	No SS-31 trial registry entry is available for ME/CFS or long COVID. The support is anecdotal and forum-based, not a controlled trial in either condition.	ME/CFS and long-COVID communities often explain symptoms through mitochondrial dysfunction, so SS-31 is a predictable target for personal-use reports. That rationale remains indirect for this use.	Reddit threads in ME/CFS and long-COVID communities describe personal experiments with SS-31 or SS-31 plus MOTS-c. Some recovery-style reports mention complex stacks including BPC-157, breathwork, hyperbaric oxygen, Selank, CBD, and other interventions, which makes attribution especially weak.	These are anecdotes, not ME/CFS or long-COVID trials. Many reports stack SS-31 with MOTS-c, BPC-157, breathwork, hyperbaric oxygen, Selank, CBD, NAD/NR, pacing, or diet changes, so it is hard to know how much credit to give SS-31 by itself. Reddit
SS-31 supports weight loss or fat loss.	The human development program was not built around obesity, weight loss, or fat loss. The main human programs involve Barth syndrome, PMM, dry AMD, LHON, heart failure, and renal revascularization.	Mitochondrial function can sound metabolically relevant, but that is too broad to support a fat-loss claim for this molecule.	Weight-loss or body-composition interest may appear around mitochondrial and longevity marketing. The reviewed human programs do not center on obesity or body-composition outcomes, so weight-loss claims are weak metabolic extrapolation.	Weight loss is a weak fit for SS-31. In metabolic discussion, it fits better as mitochondrial context than as a fat-loss peptide. PMID 37268435 PMID 32068002 PMID 36246181 PMID 37923251 PMID 28916603
A vendor COA shows injectable quality.	The approved product is an FDA-reviewed sterile injection. Vendor listings and COAs may describe identity or purity, but they do not show whether a research vial works in people or has comparable sterile-product controls.	The receptor mechanism is not the issue here. The product issues are identity, sterility, endotoxin, stability, concentration, representative lot sampling, shipping conditions, labeling, and chain of custody.	The vendor examples describe research-only material, lyophilized vials, HPLC-MS or HPLC purity claims, and downloadable lab results. Some sites explicitly state the material is for research or analytical use only and not for human or animal use.	A COA can be a limited quality clue. It is still a long way from a gray-market vial to Forzinity-level product control. FDA Vendor
Online SS-31 schedules set a practical dosing standard.	The FDA label and trial records provide documented doses and schedules, but online protocol-style material describes market practice rather than a treatment standard.	Mitochondrial targeting is not enough to set an off-label wellness dose, route, or cycle length.	One protocol-style site describes subcutaneous 10 mg daily loading for 5 to 7 days followed by 5 to 10 mg daily maintenance for 4 to 8 weeks. That is a market schedule, not a controlled trial regimen.	This pattern circulates online as a market schedule, not label dosing or controlled-trial exposure. Online peptide schedule Vendor

Bottom line

Main takeaway

If you just heard the name

Yes, SS-31 is FDA-approved: for muscle strength in one rare genetic disease, based on evidence FDA still wants confirmed. That sentence does not extend to energy, aging, or anything sold in a research vial.

If you are comparing mitochondrial peptides

Read SS-31 as two stories running in parallel: a legitimate drug program with one narrow win and several expensive misses, and a wellness market that borrows the win and ignores the misses.

Primary evidence hierarchy

The regulatory package, label, approval letter, Drug Trials Snapshot, CRL, and advisory committee record, is the spine. PMM, AMD, LHON, heart, and renal data each stand on their own populations and endpoints, and none of them props up off-label use.

Identity

What it is

SS-31 is the development name for elamipretide, a tetrapeptide with the sequence D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2. It was engineered to concentrate at the inner mitochondrial membrane and bind cardiolipin, the lipid that organizes the membrane's folds and its energy-producing machinery.

That target made it a plausible candidate wherever mitochondria fail: Barth syndrome, where cardiolipin itself is defective, plus mitochondrial myopathy, heart failure, and energy-hungry tissue like retina and optic nerve. The plausibility has been tested hard, and the results look like real drug development: early signals, a negative phase 3 in myopathy, a missed structural endpoint in heart failure, and one narrow accelerated approval in Barth syndrome.

Meanwhile the name escaped into the wellness market, where the same molecule is sold as a mitochondrial tonic for energy, recovery, and aging. Nothing in the trial record supports that use, and the research vials being sold are not Forzinity: no reviewed sterility, no validated concentration, no label.

How people talk about it online

Online SS-31 talk splits cleanly in two. The published side is drug development: Forzinity, Barth syndrome, and a trial record with more misses than hits. The other side is mitochondrial-support culture: clinic pages, fatigue forums, ME/CFS and long-COVID threads, and stack logs pairing it with MOTS-c or NAD+.

The personal reports are impossible to weigh. People describing SS-31 experiments are usually running several interventions at once: BPC-157, breathwork, hyperbaric oxygen, pacing, supplements, so even sincere reports cannot say what the peptide did.

Gray-market listings present lyophilized vials with HPLC paperwork and research-use disclaimers. Whatever those vials contain, they are a different product from the FDA-reviewed sterile injection, and the molecule's trial history does not transfer to them.

Use context

Routes, doses, and cycle patterns

Forzinity labeling and human studies give the most traceable route and schedule details. Clinic claims, Reddit and forum reports, vendor vial formats, and online cycles explain off-label use discussions. They are market examples, not the same thing as labeled dosing or trial regimens.

Human studies and product labels

Forzinity labeled Barth syndrome regimen

Purpose: Muscle strength in Barth syndrome patients weighing at least 30 kg
Context: FDA-approved product label; accelerated approval
Route: Subcutaneous
Amount: 40 mg; supplied as 80 mg/mL solution in a 280 mg / 3.5 mL vial
Frequency: Once daily
Duration: Ongoing labeled treatment context

This is the main FDA-labeled dose pattern. It applies to the approved product and the approved Barth syndrome indication, not to every SS-31 vial sold online.

FDA

Severe renal impairment label adjustment

Purpose: Labeled dose modification in adults with severe renal impairment not on dialysis
Context: FDA-approved product label
Route: Subcutaneous
Amount: 20 mg when eGFR is less than 30 mL/minute and the patient is not on dialysis
Frequency: Once daily
Duration: Ongoing labeled treatment context

Elamipretide is substantially recovered in urine, and the label also flags MATE1 inhibition in vitro. The label does not provide enough information for dialysis dosing or pediatric renal-impairment dosing.

FDA

SPIBA-201 randomized Barth syndrome period

Purpose: Barth syndrome functional endpoints and safety
Context: Randomized, double-blind, placebo-controlled crossover trial
Route: Subcutaneous
Amount: 40 mg
Frequency: Once daily
Duration: 12 weeks

The randomized period did not show superiority on 6-minute walk distance or fatigue. The accurate claim is narrower: open-label knee extensor strength gains supported accelerated approval.

FDA

SPIBA-201 open-label extension

Purpose: Barth syndrome knee extensor muscle-strength follow-up
Context: Open-label extension used in the accelerated-approval support package
Route: Subcutaneous
Amount: 40 mg
Frequency: Once daily
Duration: Designed for up to 192 weeks

Knee extensor strength gains in open-label follow-up became the intermediate endpoint supporting accelerated approval. Open-label design, small sample size, and effort-dependent endpoints are major interpretive limits.

FDA

Barth syndrome confirmatory trial requirement

Purpose: Verification of clinical benefit after accelerated approval
Context: FDA postmarketing requirement
Route: Not fully specified in FDA's public requirement summary
Amount: FDA's public requirement summary does not list an amount
Frequency: FDA's public requirement summary does not list a schedule
Duration: FDA-required confirmatory trial; protocol submitted 09/2025 and final report planned 03/2030

The required trial is randomized, double-blind, and placebo-controlled in Barth syndrome patients age 5 and older. It is central because the accelerated-approval endpoint has not yet been verified as clinical benefit.

FDA

Early PMM dose-escalation study

Purpose: Primary mitochondrial myopathy exercise-related signals
Context: Randomized dose-escalation human study
Route: Intravenous in the early dose-escalation program
Amount: Multiple ascending doses in the early study
Frequency: Short multi-day exposure in the early study
Duration: Short early-phase exposure

Early PMM work helped generate interest in exercise capacity, but the later phase 3 result carries more weight. The early work mainly explains why researchers kept studying the drug.

PMID 29500292

MMPOWER-2 crossover PMM study

Purpose: Primary mitochondrial myopathy exercise and fatigue outcomes
Context: Randomized crossover study
Route: Subcutaneous
Amount: 40 mg
Frequency: Once daily
Duration: 4-week active period in crossover context

This study is part of why SS-31 retained interest in PMM, but the later larger MMPOWER-3 result limits broad PMM claims.

PMID 32096613

MMPOWER-3 phase 3 PMM study

Purpose: Primary mitochondrial myopathy 6-minute walk and fatigue outcomes
Context: Phase 3 randomized placebo-controlled study
Route: Subcutaneous
Amount: 40 mg
Frequency: Once daily
Duration: 24 weeks

MMPOWER-3 provided Class I data that elamipretide did not improve the 6-minute walk test or fatigue overall at 24 weeks.

PMID 37268435 NCT03323749

NuPOWER genotype-defined mitochondrial disease study

Purpose: Nuclear-DNA-related primary mitochondrial disease
Context: ClinicalTrials.gov registry and company-reported program context
Route: Subcutaneous
Amount: Registry materials list 60 mg
Frequency: Once daily
Duration: 48 weeks

NuPOWER continues to test the genotype-subgroup hypothesis, but registry and company updates still need prospective results before supporting a PMM treatment claim.

PMID 39574155 NCT05162768

ReCLAIM dry AMD phase 1 studies

Purpose: Dry AMD visual-function and retinal-structure signals
Context: Phase 1 human ophthalmology studies
Route: Subcutaneous systemic elamipretide in the ReCLAIM program
Amount: Study-specific exposure; dose not reported in the reviewed study summary
Frequency: Study-specific exposure
Duration: Study-specific exposure

Phase 1 AMD papers reported exploratory visual-function signals, including low-luminance-related measures. They support further study, not consumer promises about vision restoration.

PMID 36246181 PMID 36246187

ReCLAIM-2 dry AMD phase 2 study

Purpose: Geographic atrophy growth, visual function, and ellipsoid-zone preservation
Context: Randomized phase 2 dry AMD study
Route: Subcutaneous
Amount: 40 mg
Frequency: Once daily
Duration: 48 weeks in the cited phase 2 trial context

ReCLAIM-2 keeps the ophthalmology program active and gives a concrete study context for the eye claims. It is still investigational, not an approved ocular use.

PMID 39605874 NCT03891875

ReNEW dry AMD phase 3 registry

Purpose: Dry AMD with geographic atrophy
Context: Phase 3 clinical-trial registry
Route: Subcutaneous
Amount: Not reported in the cited registry summary
Frequency: Once daily
Duration: 96-week masked period; approximately 104 weeks total participation in reviewed trial materials

ReNEW shows dry AMD is still an active phase 3 question. Until results are published, it shows the route, duration, and study direction, not whether elamipretide improves vision or changes practical dosing.

NCT06373731

LHON topical ophthalmic study

Purpose: Leber hereditary optic neuropathy visual outcomes and safety
Context: Small phase 2 topical ophthalmic study
Route: Topical ophthalmic
Amount: Program materials describe 1% elamipretide topical ophthalmic solution
Frequency: Study-specific topical dosing
Duration: Study-specific exposure

This used a different route and product setup than subcutaneous Forzinity or research vials. It is exploratory ophthalmology research, not a subcutaneous peptide-clinic protocol.

PMID 37923251 NCT02693119 Program material

Heart failure single-infusion study

Purpose: HFrEF mechanistic and left-ventricular-volume signals
Context: Randomized placebo-controlled single-infusion study
Route: Intravenous infusion
Amount: Study-specific infusion amount
Frequency: Single infusion
Duration: Acute study context

This study is helpful for mechanistic interest in the heart, but it does not provide enough evidence for a chronic heart-failure treatment claim.

PMID 29217757

PROGRESS-HF multiple-dose study

Purpose: HFrEF left ventricular end-systolic volume
Context: Phase 2 randomized multiple-dose study
Route: Subcutaneous
Amount: 4 mg or 40 mg arms in reviewed registry/trial summaries
Frequency: Once daily
Duration: 28 days / 4 weeks

Elamipretide was described as well tolerated, but it was not superior to placebo on the structural LVESV endpoint at 4 weeks.

PMID 32068002 NCT02788747

Renal artery stenosis PTRA pilot

Purpose: Kidney oxygenation, renal blood flow, and kidney-function outcomes around revascularization
Context: Phase 2a pilot during stent revascularization / PTRA
Route: Peri-procedural study exposure
Amount: Study-specific exposure; the cited source did not report a dose
Frequency: Peri-procedural exposure
Duration: Procedural pilot with follow-up kidney outcomes

The pilot reported attenuated postprocedural hypoxia, increased renal blood flow, and improved kidney function. It is too small and narrow to justify broad kidney-health claims.

PMID 28916603

Real-world discussion

No established community protocol

Purpose: Mitochondrial and longevity discussion
Context: Research coverage and niche vendor listings
Route: Trial work used intravenous and subcutaneous administration; community material describes subcutaneous cycles
Amount: No consistent community range; one protocol-style site describes 5 to 10 mg daily market schedules
Frequency: Not established
Duration: Not established

SS-31 (elamipretide) has a genuine clinical-trial history, and its real-world use culture stays thin compared with MOTS-c or NAD+: scattered protocol-site schedules and forum stack logs rather than a settled convention. Anything sold under this name is unverified research material.

What varies

Barth label doses, PMM trial doses, LHON topical studies, Reddit fatigue reports, vendor COAs, and online cycle pages describe different SS-31 contexts.
Goal: Barth syndrome muscle strength, PMM fatigue, dry AMD visual function, LHON optic neuropathy, HFrEF remodeling, renal revascularization, ME/CFS fatigue, cognition, longevity, and fat loss are not interchangeable.
Route: approved Forzinity is subcutaneous, early PMM and heart-failure work included intravenous exposure, LHON used topical ophthalmic solution, and gray-market pages usually imply injectable research material.
Amount: 40 mg daily is label/trial-backed in several settings; 20 mg daily is a labeled severe-renal-impairment adjustment; 5 to 10 mg online protocol cycles are weaker market material.
Duration: 12 weeks, 24 weeks, 48 weeks, 96 weeks, and 192-week extension language come from different study contexts.
Product quality: a COA or HPLC purity percentage can hint at identity or purity, but sterile injectable release testing, stability, shipping validation, labeling, and FDA-reviewed manufacturing are separate requirements.
Stacking: Reddit and forum reports may include MOTS-c, BPC-157, NAD or NR, hyperbaric oxygen, breathwork, Selank, CBD, diet changes, pacing, or other interventions.
Monitoring: the label and FDA reviews raise injection reactions, hypersensitivity, eosinophilia, severe renal impairment, MATE1/metformin interaction work, and missing pregnancy/lactation data.

Human data

Human evidence

The human record is real and mostly sobering. The strongest entry is the Forzinity approval for Barth syndrome muscle strength, and it is built on open-label strength gains after the randomized period failed to separate on walking distance or fatigue. Primary mitochondrial myopathy looked promising early, then MMPOWER-3, a proper phase 3, found no overall benefit in walk distance or fatigue at 24 weeks. Heart failure followed the same arc: mechanistic interest, then PROGRESS-HF missed its structural endpoint. The eye programs and a small kidney-procedure pilot remain exploratory. What the human data do not include is any support for the energy, anti-aging, ME/CFS, or long-COVID uses that dominate the online discussion.

Evidence maturity

SS-31 shows what the full pipeline looks like: years of trials, several failures, one narrow approval.

Mechanism

Cardiolipin-targeted mitochondrial peptide with a clear molecular rationale.

Trial programs

Mitochondrial myopathy, heart failure, and eye indications tested over years.

Mixed and failed readouts

Several indications missed their endpoints.

Narrow approval

2025 FDA approval (Forzinity) for Barth syndrome, a rare-disease indication, not longevity.

Study / evidence area	Population	Design	Product context	Main outcome	Limitations	Weight
Forzinity FDA-approved Barth syndrome label FDA	Adult and pediatric Barth syndrome patients weighing at least 30 kg	FDA accelerated approval and prescribing-information context	Approved Forzinity product	The label supports Forzinity's specific Barth syndrome claim: improving muscle strength in patients who meet the weight criterion, under accelerated approval.	Accelerated approval depends on an intermediate endpoint, and a confirmatory randomized trial is required to verify clinical benefit.	Strong for the approved Barth use; confirmatory trial results not yet reported
SPIBA-201 randomized period and open-label extension FDA	Small Barth syndrome study population	Randomized double-blind placebo-controlled crossover plus open-label extension	Controlled elamipretide development program	Randomized endpoints did not show superiority on 6-minute walk distance or fatigue; open-label follow-up showed knee extensor strength gains used for accelerated approval.	Very small sample, open-label bias, effort-dependent endpoint concerns, all-male and demographically limited study record, and confirmatory data still required.	Moderate for intermediate muscle-strength signal; weak for broad function
FDA safety and risk review package FDA	Barth syndrome development population and reviewed safety record	Regulatory safety review and REMS assessment	Approved-product review	Injection-site reactions were common, and hypersensitivity and eosinophilia were found. FDA did not require a REMS based on the reviewed risk profile.	The reviewed population is small, and postmarketing carcinogenicity and interaction work remain important open items.	Label-driven safety characterization with important unknowns
Primary mitochondrial myopathy program PMID 29500292 PMID 32096613 PMID 37268435 PMID 39574155 NCT05162768	Adults with primary mitochondrial myopathy	Early randomized studies plus phase 3 MMPOWER-3	Investigational elamipretide	Early studies suggested possible exercise-related benefit, but MMPOWER-3 did not improve 6-minute walk distance or fatigue overall at 24 weeks.	The phase 3 miss weighs against a broad PMM claim; genotype-specific claims require their own study-by-study explanation.	Mixed human data; negative overall phase 3
Dry AMD ReCLAIM and ReCLAIM-2 program PMID 36246181 PMID 36246187 PMID 39605874 NCT06373731	People with dry age-related macular degeneration, including geographic atrophy contexts	Phase 1 studies, randomized phase 2, and registered phase 3 program	Investigational ophthalmology program	Reported exploratory visual-function, low-luminance, ellipsoid-zone, or geographic-atrophy findings support continued investigation.	No approved ocular indication; no consumer vision-restoration claim.	Exploratory to moderate investigational human evidence
LHON topical ophthalmic study PMID 37923251 NCT02693119	People with Leber hereditary optic neuropathy	Small phase 2 topical ophthalmic study	Investigational topical ophthalmic elamipretide, not subcutaneous Forzinity	Reported safety, tolerability, and possible efficacy findings.	Small exploratory study; no approved LHON claim; topical route does not map to gray-market subcutaneous products.	Weak exploratory human data
HFrEF single-infusion and PROGRESS-HF studies PMID 29217757 PMID 32068002 NCT02788747	People with heart failure with reduced ejection fraction	Single-infusion randomized study plus multiple-dose phase 2 study	Investigational cardiovascular program	The single-infusion study showed mechanistic interest, but PROGRESS-HF did not improve LVESV compared with placebo at 4 weeks.	PROGRESS-HF leaves SS-31 as cardiovascular research, not a heart-failure treatment or broad cardioprotection claim.	Mixed human data with negative multiple-dose endpoint
Renal artery stenosis PTRA pilot PMID 28916603	People with atherosclerotic renal artery stenosis undergoing revascularization	Small phase 2a procedural pilot	Investigational peri-procedural use	Reported attenuated postprocedural hypoxia, increased renal blood flow, and improved kidney function.	Small, specialized, and tied to a renal revascularization procedure, so it is a kidney-procedure signal rather than a general kidney-health protocol.	Weak pilot human data
Clinic, Reddit, forum, and gray-market discussion Clinic Reddit Online peptide schedule Vendor	Clinic audiences, online communities, and self-selected users	Personal reports and market listings	Research-use vials, clinic peptide discussion, online schedules, and personal-use discussion	Real-world discussion centers on energy, recovery, aging, cognition, fatigue, ME/CFS, long COVID, and mitochondrial stacks.	Most sources are anecdotal or commercial. Products vary, dose reporting is inconsistent, and outcomes are usually subjective and heavily confounded by stacks.	Anecdotal market context; no controlled benefit signal

Cautions

Safety and unknowns

Injection-site reactions are the most visible labeled adverse-reaction theme. FDA trial materials described local administration reactions in all 12 elamipretide-treated Barth participants in the placebo-controlled trial.
Hypersensitivity and eosinophilia are named safety issues. Serious allergic reactions requiring emergency intervention have been reported, and eosinophil counts often rose after 30 or more days, typically peaking around 90 days and later normalizing or improving after discontinuation.
FDA did not require a REMS in the reviewed risk assessment, but off-label safety questions still depend on route, product quality, dose, and patient context.
The accelerated-approval endpoint has not yet been verified as clinical benefit, which is why FDA required a randomized placebo-controlled confirmatory Barth syndrome trial.
FDA required two carcinogenicity studies and a metformin interaction study. The metformin issue matters because the label states elamipretide inhibits MATE1 in vitro.
The Barth approval data came from a tiny, single-site, all-male, mostly White, and mostly non-Hispanic population, which limits generalizability to broader populations and off-label use cases.
The label does not provide pregnancy data in the intended population, lactation data, sufficient dialysis dosing information, or sufficient pediatric renal-impairment dosing information.
Gray-market or research-use products add identity, concentration, sterility, endotoxin, stability, storage, shipping, reconstitution, and dose-math risk. The name SS-31 alone does not tell you any of that.

Product quality

A vial label is only a starting point

Forzinity and research-use SS-31 are different products in practice. The approved product is a sterile aqueous solution with reviewed concentration, storage, discard timing, manufacturing, microbiology, labeling, and stability information.

Vendor examples describe lyophilized research material, purity claims, COAs, HPLC or HPLC-MS testing, and lab reports. Those details can identify the commercial claim, but they are not the same level of sterile injectable quality control as the FDA-reviewed product.

The FDA review also shows how much product-control detail sits behind Forzinity: manufacturing fixes, validated lots, shipping controls, and representative sampling.

Product identity

The vial has to be the intended elamipretide material, not merely a product page using the same name.

Sterility and endotoxin

Purity percentage and identity testing leave sterile injectable risk unresolved.

Concentration and dose math

The approved product is 80 mg/mL, while research vials may be lyophilized and require reconstitution. Copying a dose across products changes risk.

Stability and storage

The approved product has defined refrigerated storage and discard timing; gray-market shipping, storage, and reconstitution conditions may differ.

Lot representativeness

A posted COA may not match the vial someone actually has.

Market claims

A research-use or clinic-marketed listing can borrow the molecule's study history while selling or describing a product that has not been reviewed like the approved drug.

Mechanism

How it is proposed to work

SS-31 is designed to concentrate around the inner mitochondrial membrane and associate with cardiolipin, a membrane lipid that helps organize mitochondrial structure and energy production. The simple idea is that stabilizing cardiolipin-rich mitochondrial membranes may help preserve bioenergetic function under stress.

Mechanistic literature describes SS-31 as more specific than a generic antioxidant. It is tied to cardiolipin interaction, inner-membrane surface electrostatics, cristae organization, respiratory-chain function, reduced electron leak, reactive oxygen species handling, and mitochondrial protein-interaction patterns.

Barth syndrome is the clearest disease-mechanism fit because cardiolipin abnormality is central to the disorder. Even there, FDA required confirmatory clinical-benefit testing.

Mitochondrial plausibility is only the starting point. PMM, heart failure, ophthalmology, renal procedural injury, fatigue, aging, and cognition all measure different outcomes.

FAQ

Common questions

Is SS-31 the same as elamipretide?

SS-31 is the research-code name commonly used for elamipretide. Forzinity is the approved product name; non-label SS-31 products are different products.

FDA

Does Forzinity approval make SS-31 a general mitochondrial peptide?

No. FDA accelerated approval is for a narrow Barth syndrome population, not general benefits for fatigue, performance, aging, cognition, or non-label mitochondrial-support claims.

FDA

What practical details are available?

The practical details include label doses, trial routes, online cycle claims, and product-quality issues. They are comparison points, not a personal protocol or product recommendation.

Details

Technical details

SS-31 / Elamipretide technical details

Canonical name

Elamipretide

Common names

SS-31; MTP-131; Bendavia; elamipretide HCl; Forzinity

Class

Mitochondria-targeted tetrapeptide; cardiolipin-associated

Sequence

D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2

Approved product

Forzinity

Approved U.S. indication

Barth syndrome muscle strength in patients weighing at least 30 kg

Approval type

FDA accelerated approval with confirmatory trial required

Approved route

Subcutaneous injection

Approved formulation

80 mg/mL sterile solution; 280 mg / 3.5 mL vial

Renal-impairment adjustment

20 mg once daily when eGFR is less than 30 and not on dialysis

Pharmacokinetic notes

About 92% SC bioavailability; peak 0.5 to 1 hour; urinary recovery

Interaction note

In vitro MATE1 inhibition; FDA required a metformin interaction study

Investigational programs

PMM, genotype-defined disease, dry AMD, LHON, HFrEF, and renal PTRA

Real-world discussion clusters

Energy, recovery, aging, cognition, ME/CFS, long COVID, and stacks

Best-supported use

Approved Barth support; mixed or exploratory elsewhere

Product distinction

Forzinity is reviewed; gray-market vials need separate quality proof

PK note

Trials used intravenous or subcutaneous administration. Pharmacokinetic detail for other routes is not published, and there is no community PK picture.

Sources

References

1.
FDA. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome 2025.
Accessed 2026-06-09.
FDA announcement for accelerated approval of Forzinity (elamipretide) injection for Barth syndrome in patients weighing at least 30 kg.
2.
FDA. FORZINITY (elamipretide) injection prescribing information 2025.
Accessed 2026-06-09.
Prescribing information identifying Forzinity as a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.
3.
FDA. Drug Trials Snapshots: Forzinity 2026.
Accessed 2026-06-09.
FDA snapshot summarizing the approval-supporting trial population, accelerated-approval posture, endpoint limitations, and common injection-site reactions.
4.
ClinicalTrials.gov. A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome 2024.
NCT03098797 Accessed 2026-06-09.
Registry record for the randomized crossover Barth syndrome trial and open-label treatment extension.
5.
PubMed. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism 2021.
doi:10.1038/s41436-020-01006-8 PMID:33077895 Accessed 2026-06-09.
Peer-reviewed Barth syndrome randomized crossover trial and open-label extension source; the randomized portion did not meet the original primary endpoints.
6.
PubMed. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome 2022.
doi:10.1186/s13023-022-02469-5 PMID:36056411 Accessed 2026-06-09.
Natural-history comparison source for longer-term Barth syndrome context; non-randomized design requires cautious framing.
7.
PubMed. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER 2024.
PMID:38602181 Accessed 2026-06-09.
Open-label extension source for longer-term Barth syndrome safety, tolerability, and functional outcomes.
8.
PubMed. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects 2025.
PMID:40294492 Accessed 2026-06-09.
Mechanism review source for cardiolipin interactions, mitochondrial membrane effects, and clinical-trial context.
9.
PubMed. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial 2023.
PMID:37268435 Accessed 2026-06-09.
Phase 3 primary mitochondrial myopathy trial source; it reports no significant benefit versus placebo on primary walking-distance or fatigue endpoints.
10.
PubMed. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial 2024.
doi:10.1186/s13023-024-03421-5 PMID:39574155 Accessed 2026-06-09.
Post hoc PMM analysis source; exploratory findings should not override the overall phase 3 result.
11.
PubMed. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation 2024.
PMID:39605874 Accessed 2026-06-09.
Randomized phase 2 age-related macular degeneration source; it reports the primary endpoints as not met.
12.
FDA. FDA Approval Letter for NDA 215244, Forzinity (elamipretide) 2025.
Accessed 2026-06-10.
Covers accelerated approval status, postmarketing confirmatory-trial requirement, planned confirmatory timeline, and regulatory caveats.
13.
FDA. FDA grants accelerated approval to first treatment for Barth syndrome 2025.
Accessed 2026-06-10.
FDA approval summary and public approval date.
14.
FDA. FDA Drug Trials Snapshot: Forzinity 2026.
Accessed 2026-06-10.
Covers trial population, efficacy endpoint interpretation, local administration reactions, and trial-summary wording.
15.
FDA. FDA Integrated Review for NDA 215244, Forzinity (elamipretide) 2025.
Accessed 2026-06-10.
Covers regulatory evidence interpretation, clinical review details, safety limitations, and labeling caveats.
16.
FDA. FDA Risk Assessment and REMS Review for Forzinity 2025.
Accessed 2026-06-10.
Covers hypersensitivity, eosinophilia, REMS determination, and concrete safety-risk wording.
17.
FDA. FDA Product Quality Review for NDA 215244, Forzinity 2025.
Accessed 2026-06-10.
Covers approved-product quality, sterility, stability, manufacturing, microbiology, shelf-life, GMP, PPQ, shipping validation, and representative sampling.
18.
FDA. FDA Complete Response Letter for NDA 215244, elamipretide 2025.
Accessed 2026-06-10.
Documents the mixed regulatory story, randomized Barth endpoint limitations, and why accelerated approval wording needs caveats.
19.
FDA. FDA Cardiovascular and Renal Drugs Advisory Committee Meeting on elamipretide for Barth syndrome 2024.
Accessed 2026-06-10.
Documents advisory-committee vote history and concerns about placebo effects, open-label bias, and effort-dependent endpoints.
20.
FDA. FDA human drug compounding and unapproved-drug safety resources 2025.
Accessed 2026-06-10.
Covers product-quality and unapproved-product caveats for gray-market, compounded, and research-use peptide material.
21.
FTC. FTC Health Products Compliance Guidance 2022.
Accessed 2026-06-10.
Covers claim-substantiation standards for clinic, vendor, wellness, anti-aging, cognitive, and recovery marketing claims.
22.
PubMed. Randomized Dose-Escalation Trial of Elamipretide in Adults With Primary Mitochondrial Myopathy 2018.
doi:10.1212/WNL.0000000000005255 PMID:29500292 Accessed 2026-06-10.
Early PMM human dose-escalation evidence with route details and hypothesis-generating exercise-signal language.
23.
PubMed. A randomized clinical trial of elamipretide in adults with primary mitochondrial myopathy 2020.
doi:10.1002/jcsm.12559 PMID:32096613 Accessed 2026-06-10.
MMPOWER-2 crossover PMM protocol and early efficacy-signal discussion.
24.
PubMed. The MMPOWER-3 Randomized Clinical Trial 2023.
PMID:37268435 NCT03323749 Accessed 2026-06-10.
Negative phase 3 PMM conclusion, 24-week timeframe, 6MWT and fatigue endpoints, and the limits on broad PMM claims.
25.
ClinicalTrials.gov. MMPOWER-3 trial registry: A Trial to Evaluate Safety and Efficacy of Elamipretide in Primary Mitochondrial Myopathy 2017.
NCT03323749 Accessed 2026-06-10.
Registered MMPOWER-3 study design and daily subcutaneous exposure details.
26.
PubMed. Elamipretide in patients with primary mitochondrial myopathy and nuclear DNA mutations affecting the mitochondrial replisome: a post hoc analysis of the MMPOWER-3 trial 2024.
doi:10.1186/s13023-024-03421-5 PMID:39574155 Accessed 2026-06-10.
Genotype-subgroup and post hoc exploratory findings.
27.
ClinicalTrials.gov. NuPOWER trial registry: Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Nuclear DNA Mutations 2021.
NCT05162768 Accessed 2026-06-10.
NuPOWER study design, 48-week duration, daily subcutaneous dosing, and genotype-defined mitochondrial-disease population.
28.
PubMed. ReCLAIM phase 1 elamipretide study in dry AMD with noncentral geographic atrophy 2021.
doi:10.1016/j.xops.2021.100086 PMID:36246181 Accessed 2026-06-10.
Exploratory dry AMD visual-function and low-luminance signal source.
29.
PubMed. ReCLAIM phase 1 elamipretide study in dry AMD with high-risk drusen 2021.
PMID:36246187 Accessed 2026-06-10.
Dry AMD investigational evidence source, separate from approved ocular claims.
30.
PubMed. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation 2024.
PMID:39605874 Accessed 2026-06-10.
ReCLAIM-2 phase 2 AMD outcomes, ellipsoid-zone and visual-function discussion, and 40 mg daily / 48-week protocol details.
31.
ClinicalTrials.gov. ReCLAIM-2 trial registry for elamipretide in dry AMD 2019.
NCT03891875 Accessed 2026-06-10.
ReCLAIM-2 design and protocol details.
32.
ClinicalTrials.gov. ReNEW phase 3 trial registry: Efficacy, Safety, and Pharmacokinetics of Elamipretide in Dry AMD With Geographic Atrophy 2024.
NCT06373731 Accessed 2026-06-10.
Current investigational phase 3 dry AMD status, once-daily subcutaneous regimen, and 96-week masked period.
33.
PubMed. Topical ophthalmic elamipretide for Leber hereditary optic neuropathy 2024.
PMID:37923251 NCT02693119 Accessed 2026-06-10.
LHON topical ophthalmic route, safety/tolerability, and exploratory efficacy wording.
34.
ClinicalTrials.gov. ClinicalTrials.gov registry for topical elamipretide in Leber hereditary optic neuropathy 2016.
NCT02693119 Accessed 2026-06-10.
LHON study design and topical ophthalmic investigational setting.
35.
Program material. Stealth BioTherapeutics / UMDF LHON topical 1% elamipretide program material 2019.
Accessed 2026-06-10.
Specific topical 1% elamipretide detail from program materials.
36.
PubMed. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide 2017.
PMID:29217757 Accessed 2026-06-10.
HFrEF single-infusion mechanistic and left-ventricular-volume signal source.
37.
PubMed. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial 2020.
PMID:32068002 NCT02788747 Accessed 2026-06-10.
PROGRESS-HF design, 4-week endpoint, tolerability, and lack of superiority on LVESV.
38.
ClinicalTrials.gov. ClinicalTrials.gov registry for PROGRESS-HF elamipretide study 2016.
NCT02788747 Accessed 2026-06-10.
PROGRESS-HF registered route, dosing arms, frequency, and duration details.
39.
PubMed. Phase 2a Clinical Trial of Mitochondrial Protection With Elamipretide During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis 2017.
PMID:28916603 Accessed 2026-06-10.
Renal revascularization pilot outcomes: postprocedural hypoxia, renal blood flow, and kidney function.
40.
PubMed. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics 2014.
doi:10.1111/bph.12461 PMID:24117165 Accessed 2026-06-10.
Cardiolipin-centered mechanism, mitochondrial bioenergetics, and why SS-31 is not merely a generic antioxidant.
41.
PMC. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential 2025.
doi:10.3390/ijms26030944 Accessed 2026-06-10.
Updated mechanism, cardiolipin interaction, and broad investigational-program overview.
42.
PMC. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice 2018.
Accessed 2026-06-10.
Preclinical aging/exercise-tolerance rationale; animal evidence is separate from human longevity claims.
43.
Research brief. Cognitive Vitality Report for Researchers: SS-31 / elamipretide 2021.
Accessed 2026-06-10.
Cognition and brain-health claim limits; cognitive effects remain preclinical rather than confirmed in humans.
44.
Vendor. Pure Health Peptides SS-31 batch / product listing 2026.
Accessed 2026-06-10.
Research-use vendor listing with lab-results/COA language and product-quality cautions.
45.
Vendor. Happy Peptides SS-31 product listing 2026.
Accessed 2026-06-10.
Gray-market vial presentation, purity claims, third-party testing language, and research-only disclaimers.
46.
Vendor. Alpha Carbon Labs SS-31 product listing 2026.
Accessed 2026-06-10.
Gray-market/research-use product-quality and purity-claim source.
47.
Clinic. Optimization Clinic SS-31 page 2025.
Accessed 2026-06-10.
Clinic-style claims around energy, recovery, oxidative stress, cellular aging, cognition, and cardioprotection.
48.
Clinic. Revolution Health peptide therapy discussion including SS-31 stack discussion 2025.
Accessed 2026-06-10.
Real-world stack discussion with peptides such as BPC-157, TB-500, MOTS-c, and related mitochondrial/wellness themes.
49.
Online peptide schedule. PeptideFox SS-31 market page 2026.
Accessed 2026-06-10.
Documents an online protocol example: 10 mg daily loading for 5-7 days followed by 5-10 mg daily for 4-8 weeks. This is market material, not clinical-trial evidence.
50.
Reddit. Reddit r/cfs thread: SS-31 experiences / newly started use report 2025.
Accessed 2026-06-10.
ME/CFS personal-use anecdote clusters and subjective symptom reports.
51.
Reddit. Reddit r/cfs thread: Peptides for CFS, SS-31 / elamipretide and MOTS-c 2026.
Accessed 2026-06-10.
ME/CFS stack discussion, especially SS-31 plus MOTS-c.
52.
Reddit. Reddit r/cfs thread: recovery narrative involving CFS / long COVID, SS-31, and peptide stack context 2025.
Accessed 2026-06-10.
Long-COVID/ME-CFS anecdotal cluster with confounding stack details including BPC-157, breathwork, hyperbaric oxygen, Selank, CBD, and other interventions.
53.
Reddit. Reddit r/covidlonghaulers thread: SS-31 peptide 2026.
Accessed 2026-06-10.
Long-COVID SS-31 anecdotal discussion cluster.
54.
Reddit. Reddit r/longevity thread on FDA accelerated approval of elamipretide / SS-31 2025.
Accessed 2026-06-10.
Longevity-community discussion around FDA approval, off-label interest, and broader anti-aging extrapolation.